JP2024096688A5 - - Google Patents
Info
- Publication number
- JP2024096688A5 JP2024096688A5 JP2024027308A JP2024027308A JP2024096688A5 JP 2024096688 A5 JP2024096688 A5 JP 2024096688A5 JP 2024027308 A JP2024027308 A JP 2024027308A JP 2024027308 A JP2024027308 A JP 2024027308A JP 2024096688 A5 JP2024096688 A5 JP 2024096688A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- cells
- cell
- baff
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662346324P | 2016-06-06 | 2016-06-06 | |
| US62/346,324 | 2016-06-06 | ||
| PCT/US2017/036181 WO2017214170A2 (en) | 2016-06-06 | 2017-06-06 | Baff-r antibodies and uses thereof |
| JP2019516100A JP7275446B2 (ja) | 2016-06-06 | 2017-06-06 | Ｂａｆｆ－ｒ抗体及びその使用 |
| JP2022017156A JP7448299B2 (ja) | 2016-06-06 | 2022-02-07 | Ｂａｆｆ－ｒ抗体及びその使用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022017156A Division JP7448299B2 (ja) | 2016-06-06 | 2022-02-07 | Ｂａｆｆ－ｒ抗体及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024096688A JP2024096688A (ja) | 2024-07-17 |
| JP2024096688A5 true JP2024096688A5 (enExample) | 2025-08-27 |
| JP7778831B2 JP7778831B2 (ja) | 2025-12-02 |
Family
ID=59325613
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019516100A Active JP7275446B2 (ja) | 2016-06-06 | 2017-06-06 | Ｂａｆｆ－ｒ抗体及びその使用 |
| JP2022017156A Active JP7448299B2 (ja) | 2016-06-06 | 2022-02-07 | Ｂａｆｆ－ｒ抗体及びその使用 |
| JP2024027308A Active JP7778831B2 (ja) | 2016-06-06 | 2024-02-27 | Ｂａｆｆ－ｒ抗体及びその使用 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019516100A Active JP7275446B2 (ja) | 2016-06-06 | 2017-06-06 | Ｂａｆｆ－ｒ抗体及びその使用 |
| JP2022017156A Active JP7448299B2 (ja) | 2016-06-06 | 2022-02-07 | Ｂａｆｆ－ｒ抗体及びその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US11136405B2 (enExample) |
| EP (2) | EP4628094A2 (enExample) |
| JP (3) | JP7275446B2 (enExample) |
| CN (2) | CN109641957B (enExample) |
| WO (1) | WO2017214170A2 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150320799A1 (en) | 2012-12-20 | 2015-11-12 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| JP7282521B2 (ja) | 2016-04-08 | 2023-05-29 | パーデュー・リサーチ・ファウンデイション | Ｃａｒ ｔ細胞療法のための方法および組成物 |
| EP4628094A2 (en) | 2016-06-06 | 2025-10-08 | City of Hope | Baff-r antibodies and uses thereof |
| WO2018160622A1 (en) | 2017-02-28 | 2018-09-07 | Endocyte, Inc. | Compositions and methods for car t cell therapy |
| AU2019209432A1 (en) | 2018-01-22 | 2020-08-06 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Methods of use for CAR T cells |
| WO2019165237A1 (en) | 2018-02-23 | 2019-08-29 | Endocyte, Inc. | Sequencing method for car t cell therapy |
| AU2019404282A1 (en) * | 2018-12-19 | 2021-07-01 | City Of Hope | BAFF-R bispecific T-cell engager antibody |
| CN113874391B (zh) * | 2019-02-20 | 2025-10-28 | 希望之城公司 | 靶向baff-r/cd19的嵌合抗原受体修饰的t细胞及其用途 |
| WO2021163989A1 (en) * | 2020-02-21 | 2021-08-26 | Yinnuolai Biotech Ltd. | Anti-baff receptor antibodies and uses thereof |
| CN111499723B (zh) * | 2020-05-28 | 2021-04-09 | 广州百暨基因科技有限公司 | 一种嵌合抗原受体及其应用 |
| JP2023536596A (ja) * | 2020-08-04 | 2023-08-28 | ノバルティス アーゲー | Ｂ細胞悪性腫瘍の治療 |
| WO2022031568A1 (en) * | 2020-08-04 | 2022-02-10 | Novartis Ag | Treatment of cll |
| CN114149504B (zh) * | 2020-09-07 | 2024-01-12 | 白先宏 | Baff-r结合分子及其应用 |
| CN116390933A (zh) | 2020-11-06 | 2023-07-04 | 诺华股份有限公司 | 治疗b细胞恶性肿瘤的抗cd19剂和b细胞靶向剂组合疗法 |
| EP4342913B1 (en) * | 2021-05-19 | 2025-12-17 | Shanghai Escugen Biotechnology Co., Ltd. | Chimeric antigen receptor molecule for specifically recognizing baff-r and application of chimeric antigen receptor molecule |
| WO2023056243A1 (en) * | 2021-09-29 | 2023-04-06 | Dragonfly Therapeutics, Inc. | Antibodies targeting baff-r and use thereof |
| JP2025523874A (ja) * | 2022-07-19 | 2025-07-25 | ノバルティス アーゲー | Ｂａｆｆ又はｂａｆｆ受容体阻害抗体でのａｉｈａの治療 |
| WO2024197157A1 (en) | 2023-03-21 | 2024-09-26 | Biograph 55, Inc. | Cd19/cd38 multispecific antibodies |
| WO2025067496A1 (zh) * | 2023-09-28 | 2025-04-03 | 南京驯鹿生物技术股份有限公司 | 靶向baff-r的全人源抗体、car-t细胞及其应用 |
| CN117783521B (zh) * | 2023-11-23 | 2025-03-04 | 中国农业科学院兰州兽医研究所 | 检测非洲猪瘟病毒p30蛋白抗体的竞争ELISA试剂盒 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| AU665190B2 (en) | 1990-07-10 | 1995-12-21 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| CA2124967C (en) | 1991-12-17 | 2008-04-08 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| US5241051A (en) * | 1992-04-24 | 1993-08-31 | Research Development Foundation | Oncoinhibin |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US6066718A (en) | 1992-09-25 | 2000-05-23 | Novartis Corporation | Reshaped monoclonal antibodies against an immunoglobulin isotype |
| EP1210425B2 (en) * | 1999-08-17 | 2015-06-17 | Biogen MA Inc. | Baff receptor (bcma), an immunoregulatory agent |
| WO2004006955A1 (en) | 2001-07-12 | 2004-01-22 | Jefferson Foote | Super humanized antibodies |
| KR20070107687A (ko) | 2004-12-31 | 2007-11-07 | 제넨테크, 인크. | Ｂｒ３과 결합하는 폴리펩티드, 및 그의 용도 |
| JP5767109B2 (ja) * | 2008-07-17 | 2015-08-19 | ノバルティス アーゲー | 治療抗体を用いる組成物及び方法 |
| US20130164851A1 (en) * | 2010-03-26 | 2013-06-27 | Alnylam Pharmaceuticals, Inc. | Gene amplification and transfection methods and reagents related thereto |
| TWI667346B (zh) * | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | 促進抗原消失之具有經修飾的FcRn親和力之抗體 |
| WO2013013013A2 (en) * | 2011-07-21 | 2013-01-24 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for producing modified glycoproteins |
| GB201208370D0 (en) * | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Antibodies |
| TW201425336A (zh) * | 2012-12-07 | 2014-07-01 | Amgen Inc | Ｂｃｍａ抗原結合蛋白質 |
| GB201412658D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
| MX389663B (es) * | 2014-10-14 | 2025-03-20 | Novartis Ag | Moleculas de anticuerpo que se unen a pd-l1 y usos de las mismas. |
| JP6158865B2 (ja) | 2015-06-30 | 2017-07-05 | 株式会社リクルートホールディングス | 顧客情報提供システム及びその制御方法並びにコンピュータプログラム |
| US11326182B2 (en) * | 2016-04-29 | 2022-05-10 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| EP4628094A2 (en) | 2016-06-06 | 2025-10-08 | City of Hope | Baff-r antibodies and uses thereof |
-
2017
- 2017-06-06 EP EP25194208.2A patent/EP4628094A2/en active Pending
- 2017-06-06 WO PCT/US2017/036181 patent/WO2017214170A2/en not_active Ceased
- 2017-06-06 CN CN201780034709.5A patent/CN109641957B/zh active Active
- 2017-06-06 EP EP17739364.2A patent/EP3464374B1/en active Active
- 2017-06-06 JP JP2019516100A patent/JP7275446B2/ja active Active
- 2017-06-06 CN CN202211122109.3A patent/CN116041514A/zh active Pending
- 2017-06-06 US US16/307,434 patent/US11136405B2/en active Active
-
2021
- 2021-08-16 US US17/403,698 patent/US11981740B2/en active Active
-
2022
- 2022-02-07 JP JP2022017156A patent/JP7448299B2/ja active Active
-
2024
- 2024-02-27 JP JP2024027308A patent/JP7778831B2/ja active Active
- 2024-04-03 US US18/626,119 patent/US20240287200A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024096688A5 (enExample) | ||
| CN110799539B (zh) | 抗4-1bb抗体及其制备和使用方法 | |
| JP2020522513A5 (enExample) | ||
| JP2024119853A5 (enExample) | ||
| JP2024024114A5 (enExample) | ||
| JP7731979B2 (ja) | 特異性が増強した二重特異性抗体（ｓｅｂａ） | |
| JP7720989B2 (ja) | Ｅｇｆｒ及びｈｅｒ３を標的とする二重特異性四価抗体 | |
| JP2020522562A5 (enExample) | ||
| JPWO2020159368A5 (enExample) | ||
| JPWO2020123664A5 (enExample) | ||
| JP7641292B2 (ja) | 抗ｃｄ１９抗体、その使用方法及び製造方法 | |
| JPWO2023098888A5 (enExample) | ||
| JPWO2020218951A5 (enExample) | ||
| JPWO2023025215A5 (enExample) | ||
| JPWO2020132291A5 (enExample) | ||
| JPWO2020205499A5 (enExample) | ||
| JPWO2022204267A5 (enExample) | ||
| JPWO2021003357A5 (enExample) | ||
| JPWO2023078382A5 (enExample) | ||
| US20250376531A9 (en) | Anti-4-1bb antibodies and methods of making and using thereof | |
| JPWO2023028501A5 (enExample) | ||
| JPWO2021110990A5 (enExample) | ||
| JPWO2022101458A5 (enExample) | ||
| TW202246343A (zh) | 抗ｃｘｃｒ２抗體及其用途 | |
| JPWO2022165258A5 (enExample) |